WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that it has entered into an agreement with Walgreens Co. The deal will see YCANTH™, the first FDA-approved therapy for molluscum contagiosum, distributed through Walgreens’ specialty pharmacy. This partnership bolsters Verrica’s existing specialty pharmacy, Nufactor, which continues to play a crucial role in raising awareness of YCANTH therapy among high volume dermatology and pediatric medical practices.
The agreement marks a pivotal point in Verrica’s strategy to increase access to YCANTH, especially for the millions of adults and children affected by molluscum contagiosum each year. This viral skin disease has been a significant unmet medical need in dermatology, and the collaboration with Walgreens represents a shared commitment to address this gap.
“We are excited to enter into this agreement with Walgreens to help bring YCANTH to the millions of adults and children who contract this viral skin disease each year,” stated Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “Walgreens and Verrica mutually recognize the need to address this significant unmet medical need in dermatology, and we look forward to working together to provide greater access to YCANTH for patients in need.”
White also emphasized Verrica’s ongoing relationship with Nufactor, commending them as an ‘extraordinary partner.’ As Verrica continues its mission to meet unaddressed medical needs, partnerships with key players like Walgreens and Nufactor position the company well for future growth and impact, offering shareholders promising prospects for value creation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.